E10 M06 M32 M34 C18 Z94.0
Conditions
Interventions
Group 1: Manifested Type 1 Diabetes Mellitus patients (one single blood sample collection during one visit) - serves as control group [n=70]
Group 2: Manifested Type 1 Diabetes Mellitus patients (one
Sponsors
Medizinische Universität Graz, Department für Innere Medizin, Abteilung für Endokrinologie und Diabetologie
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Group 1: Healthy participants: healthy participants with no history of autoimmune diseases, transplantation or cancer diseases / Group 2: Type 1 Diabetes Mellitus patients: Manifested type 1 diabetes mellitus as defined by treating physicians / Group 3: Rheumatoid Arthritis patients: Manifested rheumatoid arthritis as defined by 2010 ACR/EUCLAR criteria / Group 4: Systemic Lupus erythematodes patients: Manifested systemic lupus erythematodes as defined by the 2012 SLICC crietria / Group 5: Systemic sclerosis patients: Manifested systemic slcerosis as defined by the EULAR/ACR 2013 classification criteria / Group 6: Cancer patients: Histologically confirmed colo-rectal cancer / Group 7: Kidney transplant recipients: Patients who received a first kidney transplantation
Exclusion criteria
Exclusion criteria: Exclusion criteria for all patients involved in this study: pregnancy; acute or chronic infection / Exclusion criteria per defined study-subgroup: Group 1: Healthy participants: any history of autoimmune diseases, transplantation or cancer diseases; glucocorticoid or immunosuppressive therapy within the last 3 months; manifest Type 2 diabetes mellitus / Group 2: Type 1 Diabetes Mellitus patients: glucocorticoid or immunosuppressive therapy within the last 3 months; neoplastic diseases / Group 3: Rheumatoid Arthritis patients: neoplastic diseases / Group 4: Systemic Lupus erythematodes patients: neoplastic diseases / Group 5: Systemic sclerosis patients: neoplastic diseases / Group 6: Cancer patients: ongoing chemotherapy; ongoing immunotherapy; ongoing therapy with biologicals; existence of an auto-immune disease; manifest type 2 diabetes mellitus disease / Group 7: Kidney transplant recipients: patients receiving a second, third or fourth kidney transplant; glucocorticoid or immunosuppressive therapy within the lat 3 months, AB0-incompative kidney transplantation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in the expression of activation markers of T and B cell subtypes involved in immune regulation. Differences in the expression of activation markers on T and B cell subtypes involved in pro-inflammatory processes. The cellular expression of molecular biomarkers for immune-regulation or inflammatin in the context of autoimmunity, cancer and transplant rejection will be quantified by FACS technology (Flow Cytometry). Whole blood will be used for the isolation of Peripheral Blood monoclonal antibodies for the quantification of distinct biomarkers. Monoclonal antibodies will be used for the staining of surface and intracellular markers (BD Biosciences, USA). | — |
Countries
Austria
Contacts
Public ContactHarald Sourij
Medizinische Universität Graz, Department für Innere Medizin, Abteilung für Endokrinologie und Diabetologie
Outcome results
None listed